ArticleBreast (Edinburgh, Scotland)2026

Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.

Shixian Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.